Introduction {#S1}
============

Muscarinic acetylcholine receptors (M~1~ -- M~5~) are GPCRs that regulate the activity of a diverse array of central and peripheral functions in the human body, including the parasympathetic actions of acetylcholine^[@R1]^. The M~2~ muscarinic receptor subtype plays a key role in modulating cardiac function and many important central processes, such as cognition and pain perception^[@R1]^. As it was among the first GPCRs to be purified^[@R2]^ and cloned^[@R3]^, the M~2~ receptor has long served as a model system in GPCR biology and pharmacology. Muscarinic receptors have attracted particular interest due to their ability to bind small molecule allosteric modulators^[@R4]^. Since allosteric sites are often less conserved than the orthosteric binding site, some ligands binding to allosteric sites show substantial subtype selectivity^[@R5],[@R6]^. Such agents hold great promise for the development of drugs for the treatment of conditions, including diseases of the central nervous system and metabolic disorders. Though crystal structures were recently obtained for inactive states of the M~2~ and M~3~ muscarinic receptors^[@R7],[@R8]^, there are no structures of a GPCR bound to an allosteric modulator.

The binding of an agonist to the extracellular side of a GPCR results in conformational changes that enable the receptor to activate heterotrimeric G proteins. Despite the importance of this process, only the β~2~AR and rhodopsin have been crystallized in fully active conformations^[@R9]-[@R13]^. Crystallization of active-state GPCRs has been challenging due to their inherent conformational flexibility and biochemical instability^[@R14]^. To better understand the mechanistic details underlying GPCR activation and allosteric modulation, we solved X-ray crystal structures of the M~2~ receptor bound to the high affinity agonist iperoxo^[@R15]^ alone and in combination with LY2119620, a positive allosteric modulator.

Conformational selection of nanobodies {#S2}
======================================

Initial crystallization attempts with M~2~ receptor bound to agonists were unsuccessful, likely due to the flexibility of the intracellular receptor surface in the absence of a stabilizing protein. We thus sought to obtain a 'G protein mimetic' nanobody for the M~2~ receptor to facilitate crystallization of the β~2~AR in an active conformation^[@R11]^. Llamas were immunized with M~2~ receptor bound to the agonist iperoxo, and a post-immune single variable domain (V~HH~) nanobody cDNA library was constructed and displayed on the surface of yeast ([Fig. 1a](#F1){ref-type="fig"}).

An essential component for the selection of active-state stabilizing nanobodies was simultaneous staining of yeast with both agonist and inverse-agonist occupied M~2~ receptor populations, which were distinguishably labeled with separate fluorophores. This allowed the use of fluorescence-activated cell sorting (FACS) to select those clones binding only agonist-occupied receptor ([Fig. 1b](#F1){ref-type="fig"}; see Online Methods). To ensure that the different fluorophore-conjugated receptors represent distinct receptor populations requires that at least one receptor population must be bound to an exceptionally high-affinity or irreversible ligand. We therefore developed a covalent muscarinic receptor agonist for use in selection experiments. This has precedent in an acetylcholine mustard^[@R16]^, which is thought to react with the binding site residue Asp103^3.32^ to form a covalent adduct^[@R17]^. Accordingly, we synthesized an analogous "iperoxo mustard," which we call FAUC123 ([Supplementary Methods](#SD1){ref-type="supplementary-material"}). We found that FAUC123 bound covalently and was able to induce activation of the M~2~ receptor ([Extended Data Fig. 1](#F6){ref-type="fig"}), thereby allowing simultaneous staining of yeast with agonist- and antagonist-bound M~2~ receptor labeled with distinct fluorophores for each population.

After nine rounds of conformational selection, almost all remaining yeast cell clones preferentially bound FAUC123-occupied receptor ([Fig. 1d](#F1){ref-type="fig"}). Three clones in particular, Nb9-1, Nb9-8, and Nb9-20 ([Fig. 2a](#F2){ref-type="fig"}; see Online Methods) exhibited strong, conformationally-selective staining on yeast ([Fig. 2b](#F2){ref-type="fig"}). All three nanobodies enhanced agonist affinity ([Fig. 2c](#F2){ref-type="fig"}), indicating that they stabilize active states of the receptor. Nb9-8 was the most potent, with an EC~50~ of approximately 100 nM. At high concentrations, Nb9-8 enhanced the affinity of the M~2~ receptor for iperoxo to almost the same extent as that observed in the presence of the heterotrimeric G protein G~i~ ([Fig. 2d](#F2){ref-type="fig"}).

M~2~ receptor was purified in the presence of 10 μM iperoxo, and we obtained crystals of iperoxo-bound M~2~ receptor in complex with Nb9-8 by lipidic mesophase crystallography. The structure was solved by microdiffraction at Advanced Photon Source beamline 23ID-D ([Extended Data Table 1](#T1){ref-type="table"}). Supplementing the optimized crystallization conditions with the positive allosteric modulator LY2119620 yielded crystals of M~2~ receptor simultaneously bound to both iperoxo and the modulator (see Online Methods). For all crystallization work, the agonist iperoxo was used rather than acetylcholine, as the latter is of lower affinity and is prone to hydrolysis.

Cytoplasmic changes upon activation {#S3}
===================================

A key feature of GPCR activation is an outward movement of the intracellular portion of transmembrane (TM) helices 5 and 6, creating a cavity large enough to accommodate the carboxy terminus of the G protein α subunit^[@R10],[@R13]^. While several GPCRs have been crystallized in complex with agonists, only the β~2~AR and rhodopsin show a fully active state with adequate space to allow G protein binding ([Extended Data Fig. 2](#F7){ref-type="fig"}). As anticipated based on functional studies ([Fig. 2](#F2){ref-type="fig"}), Nb9-8 binds to the intracellular surface of the receptor ([Fig. 3a](#F3){ref-type="fig"}). There is a significant outward displacement at the intracellular side of TM6, together with a smaller outward movement of TM5 and a rearrangement of TM7 around the NPxxY motif ([Fig. 3b, d](#F3){ref-type="fig"}).

Like the active states of rhodopsin and the β~2~AR, the active M~2~ receptor shows rearrangements of the highly conserved DRY motif at the intracellular side of TM3 and the NPxxY motif in TM7 ([Fig. 3c, d](#F3){ref-type="fig"}). In the active state of M~2~, Arg121^3.50^ of the DRY motif adopts an extended conformation virtually identical to that seen in metarhodopsin II and the β~2~AR-G~s~ complex ([Fig. 3c, e](#F3){ref-type="fig"}, superscript numerals refer to the Ballesteros-Weinstein numbering system), and Asp120^3.49^ is stabilized by a hydrogen bond with Asn58^2.39^ ([Fig. 3c](#F3){ref-type="fig"}). To assess the importance of Asn58^2.39^ for stabilization of the active conformation, we mutated it to alanine. The resulting mutant displayed normal ligand binding properties, but impaired ability to activate G protein ([Extended Data Fig. 3a](#F8){ref-type="fig"}; [Extended Data Table 2](#T2){ref-type="table"}). Hence, it is likely that Asn58^2.39^ either directly stabilizes the active conformation, or engages in direct interactions with G protein.

Similar to the DRY motif, the NPxxY region in TM7 shows significant rearrangements on activation ([Fig. 3d](#F3){ref-type="fig"}). Most striking is a partial "unwinding" of TM7 around Tyr440^7.53^. This positions Tyr440^7.53^ of the NPxxY motif in close proximity to the highly conserved residue Tyr206^5.58^ ([Fig. 3d](#F3){ref-type="fig"}). Although these two residues are not close enough to directly interact, their proximity may allow formation of a water-mediated hydrogen bond, as seen in the active-state structures of the β~2~AR^[@R18]^ and rhodopsin^[@R12]^. Indeed, the position of these two tyrosine residues is highly similar in the active structures of rhodopsin, β~2~AR, and the M~2~ receptor ([Fig. 3f](#F3){ref-type="fig"}), suggesting that this feature represents a hallmark of GPCR activation. In addition, a molecular dynamics study recently predicted that Tyr206^5.58^ and Tyr440^7.53^ interact in the active conformation of the M~2~ receptor^[@R19]^, although this model was in other ways dissimilar from the structures presented here.

To assess the importance of this interaction for M~2~ receptor activation, we mutated Tyr206^5.58^ to phenylalanine, eliminating its ability to interact with Tyr440^7.53^ via a bridging water molecule. The Y206F mutant receptor could no longer be activated by acetylcholine ([Extended Data Fig. 3a](#F8){ref-type="fig"}) and gave only a very weak functional response upon treatment with iperoxo. In addition, agonist affinity was reduced by greater than 10-fold ([Extended Data Table 2](#T2){ref-type="table"}), while antagonist binding was largely unaffected. These results suggest that the Tyr206^5.58^-Tyr440^7.53^ interaction stabilizes the active conformation of the receptor in a manner reminiscent of the "ionic lock" interaction^[@R20]^, which stabilizes the inactive conformation of family A GPCRs.

Activation mechanism {#S4}
====================

While activation of the β~2~AR and rhodopsin is associated with modest conformational changes in the orthosteric ligand-binding site, striking structural changes are observed in the M~2~ receptor. The activated M~2~ receptor shows a small orthosteric binding site, which completely occludes the agonist iperoxo from solvent ([Fig. 4a, b](#F4){ref-type="fig"}). Indeed, the muscarinic inverse agonist quinuclidinyl benzilate (QNB) is too large to be accommodated in this binding cavity, perhaps accounting for its ability to suppress basal activity of the M~2~ receptor.

Within the active orthosteric binding pocket, the agonist iperoxo adopts a bent conformation ([Fig. 4c](#F4){ref-type="fig"}; [Extended Data Fig. 4](#F9){ref-type="fig"}). TM helices 5, 6, and 7 move inward, toward the agonist, in the active M~2~ conformation. TM3, in contrast, undergoes a slight rotation about its axis, but has almost no inward motion toward the ligand. The largest differences between inactive and active states of the M~2~ receptor involve TM6, where an inward movement of 2 Å at the α-carbon of Asn404^6.52^ allows for formation of a hydrogen bond between its side chain and iperoxo.

Despite these activation-related structural changes, polar contacts between the agonist iperoxo and the receptor resemble those with QNB bound to the inactive M~2~ receptor. In particular, the conserved Asp103^3.32^ serves as a counter-ion to the ligand amine in both cases, and Asn404^6.52^ engages in hydrogen bonding with both ligands. The smaller size of iperoxo relative to QNB results in more limited hydrophobic contacts, however. This is particularly true along TM5, which engages the phenyl rings of QNB, but makes more limited hydrophobic contact with iperoxo in the active receptor conformation.

The hydrogen bond between Asn404^6.52^ and the iperoxo isoxazoline oxygen is analogous to the hydrogen bond between this residue and the QNB carbonyl in the inactive receptor state; however, the smaller size of iperoxo necessitates an inward motion of TM6 ([Fig. 4d, e](#F4){ref-type="fig"}). To investigate the role of this hydrogen bond in receptor activation, we mutated Asn404^6.52^ to glutamine, which, due to the longer side chain, would allow TM6 to form a hydrogen bond with iperoxo in the inactive receptor. Consistent with a previous mutagenesis study^[@R21]^, the N404Q mutant receptor failed to bind detectable amounts of \[^3^H\]-NMS, but retained the ability to specifically bind \[^3^H\]-QNB, although with 163-fold reduced affinity ([Extended Data Table 2](#T2){ref-type="table"}). Similarly, the binding affinities for acetylcholine (ACh) and iperoxo were reduced, and while the N404Q mutant was able to activate G protein in response to both iperoxo and ACh, the concentration-response curves were shifted to the right by about 100-fold ([Extended Data Fig. 3a](#F8){ref-type="fig"}), likely due to the reduced agonist binding affinities. Nevertheless, it remains possible that a structural reorientation of Asn404^6.52^ also contributes to M~2~ receptor activation.

Like Asn404^6.52^, Asp103^3.32^ plays a central role in receptor binding to iperoxo, engaging the trimethyl ammonium ion. Cation-π interactions with Tyr104^3.33^, Tyr403^6.51^ and Tyr426^7.39^ form an aromatic lid over the ligand amine ([Fig. 4f](#F4){ref-type="fig"}). To assess the contribution of Asp103^3.32^ to receptor activation, we generated and analyzed the D103E mutant M~2~ receptor, which abolished agonist-induced M~2~ receptor activation ([Extended Data Fig. 3a](#F8){ref-type="fig"}). The D103E mutant receptor bound \[^3^H\]-NMS with WT-like affinity but showed greatly reduced affinities for ACh (∼120-fold) and iperoxo (∼380-fold) ([Extended Data Table 2](#T2){ref-type="table"}), indicating that Asp103^3.32^ recognition of the ligand cation plays a critical role in both agonist binding and receptor activation.

In the active state of the M~2~ receptor, the inward motion of the upper portion of TM6 allows Tyr403^6.51^ to hydrogen bond with Tyr104^3.33^, which in turn hydrogen bonds to Tyr426^7.39^ ([Fig. 4f](#F4){ref-type="fig"}), resulting in closure of the aforementioned tyrosine lid over the agonist. Hydrogen bonding of this lid appears to be an important feature of agonist binding and activation in muscarinic receptors: mutation of any of the three tyrosines to Phe leads to impaired agonist binding in the homologous M~3~ muscarinic receptor^[@R22]^, and mutation of Tyr104^3.33^ and Tyr403^6.51^ in the M~2~ receptor has a similar effect^[@R23],[@R24]^. It should be noted that the structure of active M~2~ receptor bound to other agonists, including acetylcholine, might show differences as compared to the iperoxo-bound structure presented here.

Allosteric modulation {#S5}
=====================

Muscarinic receptors have long served as important model systems for understanding allosteric modulation of GPCR signaling^[@R5],[@R6],[@R25]^. The structures of the inactive M~2~ and M~3~ receptors confirmed that these receptors possess a large extracellular vestibule, which has been shown to bind to allosteric modulators^[@R26],[@R27]^. Situated directly above (*i.e.*, extracellular to) the orthosteric site, this cavity also shows a substantial contraction upon activation of the M~2~ receptor due to the rotation of TM6 ([Fig. 4b](#F4){ref-type="fig"}). The motion of TM6 thus provides a structural link among three regions of the receptor: the extracellular vestibule, the orthosteric binding pocket, and the intracellular surface. The structural coupling of these three regions likely accounts for the fact that allosteric modulators can affect the affinity and efficacy of orthosteric ligands and can also directly activate G proteins as allosteric agonists^[@R28]^.

To better understand how allosteric modulators act at GPCRs, we crystallized the iperoxo-occupied M~2~ receptor with LY2119620, a positive allosteric modulator ([Fig. 5a](#F5){ref-type="fig"}). This agent has not been studied previously, so we characterized its affinity for the M~2~ receptor and its allosteric interaction with iperoxo (see [Supplementary methods](#SD1){ref-type="supplementary-material"}). Radioligand binding assays revealed that LY2119620 has similar pharmacological properties to its congener, LY2033298^[@R29]^ ([Extended Data Fig. 3b](#F8){ref-type="fig"}; [Extended Data Table 3](#T3){ref-type="table"}). It exhibits strong positive cooperativity with iperoxo, and mild negative cooperativity with the inverse agonist \[^3^H\]-NMS. While LY2119620 enhances the affinity of the M~2~ receptor for iperoxo, it does not significantly change the efficacy of this orthosteric agonist ([Extended Data Table 3](#T3){ref-type="table"}). We also observed that LY2119620 is capable of directly activating the M~2~ receptor, albeit with low potency and efficacy relative to iperoxo ([Extended Data Table 3](#T3){ref-type="table"}).

Crystals of the M~2~ receptor bound to LY2119620 grew under identical conditions to those without the modulator, and the structure revealed unambiguous electron density for LY2119620 in the extracellular vestibule ([Extended Data Fig. 5](#F10){ref-type="fig"}). The modulator is positioned directly above the orthosteric agonist ([Fig. 5b](#F5){ref-type="fig"}), and it engages in extensive interactions with the extracellular vestibule. Specifically, the aromatic rings of the modulator are situated directly between Tyr177^ECL2^ and Trp422^7.35^, forming a three-layered aromatic stack. Importantly, a prior mutagenesis study implicated Tyr177^ECL2^ as a likely contact for the LY2119620 congener, LY2033298, at the M~2~ muscarinic receptor^[@R29]^. Several polar interactions are also seen ([Fig. 5c](#F5){ref-type="fig"}). In particular, Tyr80^2.61^, Asn410^6.58^, and Asn419^ECL3^ form hydrogen bonds to the modulator, and Glu172^ECL2^ engages in a charge-charge interaction with the ligand piperidine. LY2119620 binds at a site directly superficial to the orthosteric site, separated only by the tyrosine lid, with Tyr426^7.39^ interacting with both ligands.

The structure of the M~2~-iperoxo-LY2119620 complex is largely the same as that of receptor and agonist without LY2119620, suggesting that the allosteric binding site is largely pre-formed in the presence of agonist. The extracellular vestibule shows a slight additional contraction around the allosteric ligand ([Extended Data Fig. 6](#F11){ref-type="fig"}). This subtle change stands in contrast to the substantial closure of the extracellular vestibule in the two active structures relative to the inactive conformation ([Fig. 5d](#F5){ref-type="fig"}). A notable exception is Trp422^7.35^, which adopts a vertical conformation in the presence of LY2119620 and a horizontal conformation with iperoxo alone ([Extended Data Fig. 6b](#F11){ref-type="fig"}). The vertical conformation of this residue in the M~2~-iperoxo-LY2119620 complex allows it to engage in an aromatic stacking interaction with the modulator, consistent with mutagenesis results implicating Trp422^7.35^ in the binding of other allosteric modulators^[@R30]^. The effect of mutagenesis of Trp422^7.35^ on LY2119620 affinity has not been tested, however. Closure of the LY2119620 binding site in the agonist-bound M~2~ receptor allows far more extensive interactions with the modulator than the inverse agonist-bound conformation ([Fig. 5e](#F5){ref-type="fig"}), likely accounting for the ability of the modulator to enhance agonist binding affinity by preferentially slowing agonist dissociation.

The closed, active conformation of the extracellular vestibule is largely the consequence of the inward motion of TM6, which directly contacts the allosteric modulator, the orthosteric agonist, and likely the G protein as well. Stabilization of the closed extracellular vestibule by LY2119620 and other allosteric modulators may directly stabilize the open, active conformation of the intracellular side of TM6, accounting for the phenomenon of allosteric agonism in addition to positive cooperativity with orthosteric agonists. However, while the differences in TM6 between inactive and active structures can be described as a rigid-body motion, we cannot exclude the possibility that TM6 is flexible, allowing independent conformational changes in the G-protein binding site, the orthosteric site, and the extracellular vestibule.

Conclusions {#S6}
===========

The structures presented here offer insights into the structural basis for muscarinic receptor activation, and allosteric modulation by a drug-like molecule. In contrast to rhodopsin and the β~2~AR, extensive changes are seen in the orthosteric binding site and in the extracellular vestibule upon M~2~ receptor activation. The structure of active M~2~ receptor bound to the allosteric modulator LY2119620 definitively establishes the extracellular vestibule as an allosteric binding site, and shows that the allosteric modulator induces few additional structural changes as compared to those seen with orthosteric agonist alone. The structures presented here offer only a single view of an active muscarinic receptor; more work will be required to identify additional active states that may exist. Nonetheless, the information presented here provides a structural framework for future studies of GPCR activation and allostery, and may facilitate the development novel therapeutics.

Online Methods {#S8}
==============

Determination of M~2~ activation via inositol phosphate (IP) assays {#S9}
-------------------------------------------------------------------

Agonist-induced activation of the human M~2~ muscarinic receptor was studied in IP accumulation assays as described^[@R31]^. For M~2~ activation studies, HEK 293 cells were transiently cotransfected with cDNAs encoding the human M~2~ receptor (Missouri S&T cDNA Resource Center, Rolla, MO) and the hybrid G-protein Gα~qi5~ (Gα~q~ protein with the last five amino acids at the C-terminus replaced by the corresponding sequence of Gα~i~; gift from *The J. David Gladstone Institutes*, San Francisco, CA)^[@R32]^. Twenty-four hours after transfection, cells were transferred into 24 well plates at a density of 100,000 cells per well in a volume of 270 μL. After addition of 30 μL of *myo*-\[^3^H\]inositol (specific activity = 22.5 Ci/mmol, PerkinElmer, Rodgau, Germany), cells were incubated for 15 hrs. Then, medium was aspirated, the cells were washed with serum-free medium supplemented with 10 mM LiCl, and test compounds (diluted in serum-free medium supplemented with 10 mM LiCl) were added at 37 °C for 60 min. Cells were then lysed by adding 150 μL of ice-cold 0.1 M NaOH for 5 min. After neutralisation with 50 μl of 0.2 M formic acid, the cell extract was diluted in buffer (5 mM sodium tetraborate, 0.5 mM Na-EDTA) and separated by anion-exchange chromatography using an AG1-X8 resin (Bio-Rad, Munich, Germany). After washing with water and elution-buffer A (5 mM sodium tetraborate, 60 mM sodium formate) and again with water, total IP was eluted with 2.5 mL elution-buffer B (1.0 M ammonium formate) and directly collected into scintillation counting vials. Radioactivity was measured by scintillation counting after adding 2.5 ml of Emulsifier-Safe (PerkinElmer, Rodgau, Germany). Data were analysed by normalizing dpm values with 0% for the non-stimulated receptor and 100% for the full effect of the reference iperoxo. Dose-response curves were calculated by non-linear regression using the Graphpad Prism 5 software.

Irreversible activation of the M~2~ receptor was tested at 1 nM FAUC123 in comparison to the reversible ligand iperoxo (1 nM). After incubation for 30 min, the antagonist atropine (1 μM) was added to one half of the sample (buffer was added to the other half) and incubations were continued for an additional 90 min. Total IP accumulation was determined as described above.

LY2119620 pharmacology {#S10}
----------------------

To characterize the allosteric interaction between LY2119620 and iperoxo, we performed radioligand binding and cellular functional assays at the wild-type human M~2~ muscarinic receptor stably expressed in a CHO FlpIn cell line. Increasing concentrations of LY2119620 caused a modest reduction in the specific binding of the orthosteric antagonist, \[^3^H\]-NMS, indicating weak negative cooperativity, but robustly enhanced the potency of iperoxo to compete for \[^3^H\]-NMS binding, indicating positive cooperativity with the agonist ([Extended Data Fig. 3b](#F8){ref-type="fig"}). Application of an allosteric ternary complex model^[@R33],[@R34]^ to these data yielded the values shown in [Extended Data Table 3](#T3){ref-type="table"} for ligand affinity and cooperativities with agonist and antagonist. We then investigated the functional effect of LY2119620 on M~2~ muscarinic receptor signaling via monitoring receptor-mediated \[^35^S\]-GTPγS binding to activated G proteins, or phosphorylation of ERK1/2. \[^35^S\]-GTPγS binding was chosen as a proximal measure of receptor activation, while the pERK1/2 assay was chosen because it measures a downstream response that is also a point of convergence of multiple cellular pathways, some of them potentially G protein-independent. In both instances, LY2119620 caused receptor activation in its own right, indicating that the modulator can act as an allosteric agonist, while simultaneously enhancing the potency of iperoxo ([Extended Data Fig. 3b](#F8){ref-type="fig"}). Application of an operational model of allosterism^[@R35]^ to these data yielded the parameter values shown in [Extended Data Table 3](#T3){ref-type="table"}. Comparison of the binding and functional data indicated that there was no significant difference between any of the pK~B~ estimates of the affinity of LY2119620 for the allosteric site on the free receptor between assays. There was also no significant difference between the cooperativity factors with iperoxo across the assays, indicating that the molecular mechanism of action of LY2119620 is consistent with positive modulation of agonist affinity only, with minimal additional effects on agonist efficacy. This is in contrast to the more complex behavior previously noted with the congener, LY2033298, at the M~2~ receptor^[@R29]^. Full methods details are available in the [Supplementary Methods](#SD1){ref-type="supplementary-material"}.

M~2~ muscarinic receptor expression and purification {#S11}
----------------------------------------------------

The human M~2~ muscarinic receptor gene was modified to remove glycosylation sites, and to add an amino-terminal FLAG epitope tag and a carboxy-terminal 8×His tag. In addition, residues 233 -- 374 of intracellular loop 3 were deleted. This region has previously been shown to be unstructured^[@R36]^ and is not essential for G protein coupling in the homologous M~1~ muscarinic receptor^[@R37]^. This construct was expressed in *Sf9* insect cells using the BestBac baculovirus system (Expression Systems; Davis, CA). Cells were infected at a density of 4 × 10^6^ cells/mL and then incubated for two days at 27 °C. Receptor was extracted and purified in the manner described previously for the M~3~ muscarinic receptor^[@R8]^. Briefly, receptor was purified by Ni-NTA chromatography, FLAG affinity chromatography and size exclusion chromatography.

Llama immunization samples {#S12}
--------------------------

M~2~ receptor was prepared as described above, and bound to iperoxo by including it at 10 μM starting at FLAG wash steps and in all subsequent buffers. Receptor was reconstituted into phospholipid vesicles composed of DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids) and Lipid A in a 10:1 (w:w) ratio, then aliquoted at 1 mg/mL receptor concentration and frozen in 100 μL aliquots prior to injection.

Yeast display samples {#S13}
---------------------

M~2~ receptor was purified as described above with 1 μM atropine included in all buffers. Receptor was then labeled with a 5-fold molar excess of biotin-NHS ester (Sigma-Aldrich; St. Louis, MO) in buffer containing 25 mM HEPES pH 7.2. Following a 30 min incubation at room temperature and a 30 min incubation on ice, unreacted label was quenched with 50 mM tris pH 8. Directly labeled samples with fluorophore-NHS esters were prepared in a similar manner. Receptor was then desalted into buffer containing either 10 μM tiotropium, 10 μM iperoxo, or buffer containing no ligand. Receptor eluted in buffer containing no ligand was treated with 50 μM iperoxo mustard (FAUC123; see [Supplementary Information](#SD1){ref-type="supplementary-material"} for details) for 20 min at room temperature. Samples were then concentrated, aliquoted, and flash frozen with 20% (v/v) glycerol.

Crystallization samples {#S14}
-----------------------

M~2~ receptor for crystallization was prepared as described above. When bound to FLAG resin, the sample was washed with a mix of dodecyl maltoside buffer (DDM) and buffer containing 0.2% lauryl maltose neopentyl glycol detergent (MNG; Anatrace). These buffers were mixed first in a 1:1 ratio (DDM:MNG buffer), then 1:4, and 1:10 ratios. At each step the 5 mL column was washed with 10 mL of buffer at a 1 mL/min flow rate, and all buffers contained 1 μM atropine. Finally, the column was washed with 10 mL MNG buffer, and then 10 mL of low detergent buffer with agonist (0.01% MNG, 0.001% cholesterol hemisuccinate, 20 mM HEPES pH 7.5, 100 mM NaCl, 10 μM iperoxo). The sample was eluted, mixed with a 1.5-fold stoichiometric excess of Nb9-8 and a second nanobody, NbB4. This nanobody binds to an epitope different from Nb9-8, but was not resolved in the crystal structure. Following mixing, the sample was incubated 30 min on ice, then concentrated and purified by size exclusion in low detergent buffer. Eluted protein was concentrated to A~280~ = 96, and frozen in liquid nitrogen in 7 μL aliquots.

Llama immunization {#S15}
------------------

One Llama (*Lama glama*) was immunized for six weeks with 1 mg receptor in total. Peripheral blood lymphocytes were isolated from the immunized animal to extract total RNA. cDNA was prepared using 50 μg of total RNA and 2.5 μg of oligo-dN6primer. Nanobody open reading frames were amplified as described^[@R38]^.

Post-immune M~2~ receptor llama nanobody library construction {#S16}
-------------------------------------------------------------

Nanobody V~HH~ fragments were amplified by PCR using the primers pYalNB80AMPF (CATTTTCAAT TAAGATGCAG TTACTTCGCT GTTTTTCAAT ATTTTCTGTT ATTGCTAGCG TTTTAGCAAT GGCCCAGGTG CAGCTGCAGG AG) and pYalNB80AMPR (CCACCAGATC CACCACCACC CAAGTCTTCT TCGGAGATAA GCTTTTGTTC GGATCCTGAG GAGACGGTGA CCTGGGTCCC). The PCR products were then co-transformed with linearized pYal into yeast strain EBY100 as for the Nb80 affinity-maturation library, yielding a library size of 0.6×10^8^ transformants.

Selection of M~2~ G~i~-mimetic nanobodies from post-immune M~2~ llama nanobody library {#S17}
--------------------------------------------------------------------------------------

For the first round of selection, counter-selection was performed against the β~2~ receptor to remove yeast clones that bind non-specifically to membrane proteins or to secondary staining reagents. 1.0×10^9^ of induced yeast were washed with PBEM buffer and then stained in 5 mL of PBEM buffer containing 1 μM biotinylated β~2~ receptor liganded with carazolol for 1 hr at 4 °C. Yeast were then stained with streptavidin-647 as a secondary reagent and magnetically-labeled with anti-647 microbeads (Miltenyi) as described previously^[@R18]^. Positively-labeled yeast were then removed by the use of an LD column (Miltenyi); the cleared flow-through was then used for subsequent selection. Positive selection for clones recognizing the active state of the M~2~ receptor was performed by staining with 2 μM biotinylated M~2~ receptor bound to the agonist iperoxo in 5 mL PBEM buffer supplemented with 2 μM iperoxo for 1 hr at 4°C. Yeast were then washed, stained with streptavidin-647, and magnetically-labeled with anti-647 microbeads, including 1 μM iperoxo in the PBEM buffer at all steps. Magnetic separation of M~2~ receptor-binding yeast clones was performed using an LS column (Miltenyi) following the manufacturer\'s instructions. Magnetically sorted yeast were resuspended in SDCAA medium and cultured at 30°C. Rounds 2-4 were selected in a similar manner, counter-selecting against 1 μM biotinylated β~2~ receptor bound to carazolol and positively selecting using 1 μM biotinylated M~2~ receptor bound to iperoxo. For these rounds, the scale was reduced ten-fold to 1 × 10^8^ induced yeast and staining volumes of 0.5 mL.

Conformational selection was performed for rounds 5-9. For rounds 5-8, yeast were stained with 1 μM biotinylated M~2~ receptor pre-incubated with the high-affinity antagonist tiotropium for 1 hr at 4°C. Yeast were then fluorescently labeled with either streptavidin-647 or streptavidin-PE, and magnetically labeled with the corresponding anti-647 or anti-PE microbeads (Miltenyi). Depletion of inactive-state binders was carried out using an LS column. The cleared yeast were then positively selected by staining with 0.5 μM (rounds 5-7) or 0.1 μM (round 8) M~2~ receptor pre-bound to iperoxo for 1 hr at 4° C. Yeast were then fluorescently-labeled with either streptavidin-PE or streptavidin-647, using a fluorophore distinct from that used in the previous counter-selection step. Magnetic separation of agonist-occupied M~2~ receptor was performed using an LS column, as for steps 1-4. For round 9, two-color FACS was performed. Induced yeast were simultaneously stained with 1 μM Alexa647-labeled M~2~ receptor reacted with iperoxo mustard and 1 μM Alexa488-labeled M~2~ receptor pre-bound with tiotropium for 1 hr at 4°C. Alexa647 positive/Alexa488 negative yeast were purified using a FACS Jazz cell (BD Biosciences) sorter. Post-sorted yeast were plated onto SDCAA-agar plates and the nanobody-encoding sequences of several colonies were sequenced. Full sequences of clones confirmed to enhance agonist affinity are below:

Clone

Full amino acid sequence

Nb9-1

QVQLQESGGG LVQAGGSLRL SCAASGHTFS SARMYWVRQA PGKEREFVAA ISRSGFTYSA DSVKGRFTIS RDIANNTVYL QMNSLQPEDT AIYTCYAAYL DEFYNDYTHY WGLGTQVTVS S

Nb9-8

QVQLQESGGG LVQAGDSLRL SCAASGFDFD NFDDYAIGWF RQAPGQEREG VSCIDPSDGS TIYADSAKGR FTISSDNAEN TVYLQMNSLK PEDTAVYVCS AWTLFHSDEY WGQGTQVTVS S

Nb9-20

QVQLQESGGG LVQPEGSLTL ACDTSGFTMN YYAIAWFRQA PEKEREGLAT ISSIDGRTYY ADSVKGRFTI SRDSAKNMVY LQMNNLRPED TAVYYCSAGP DYSDYGDESE YWGQGTQVTV SS

Expression of MBP-nanobody fusions in *E. coli* {#S18}
-----------------------------------------------

Nanobody sequences were subcloned into a modified pMalp2x vector (New England Biolabs), containing an amino-terminal, 3C protease-cleavable maltose binding protein (MBP) tag and a carboxy-terminal 8×His tag. Plasmids were transformed into BL21(DE3) cells and protein expression induced in Terrific Broth by addition of IPTG to 1 mM at an OD~600~ of 0.8. After 24 hr of incubation at 22°C, cells were harvested and periplasmic protein was obtained by osmotic shock. MBP-nanobody fusions were purified by Ni-NTA chromatography and MBP was removed using 3C protease. Cleaved MBP was separated from the 8×His tagged nanobodies by an additional Ni-NTA purification step. The 8×His tag was subsequently removed using carboxypeptidase A.

Expression and purification of G protein {#S19}
----------------------------------------

Heterotrimeric G~i~ was prepared by expression using a single baculovirus for the human Gα~i1~ subunit and a second, bicistronic virus for human Gβ1 and Gγ2 subunits. G protein was expressed in HighFive insect cells, and then purified as described previously for G~s~^10^. In brief, G protein was extracted with cholate, purified by Ni-NTA chromatography, detergent exchanged into dodecyl maltoside buffer, and then purified by ion exchange and dialyzed prior to use.

M~2~ receptor radioligand binding assays with G protein and nanobody {#S20}
--------------------------------------------------------------------

M~2~ receptor was expressed and purified as described above. Receptor was then reconstituted into HDL particles consisting of apolipoprotein A1 and a 3:2 (mol:mol) mixture of the lipids POPC:POPG (1- palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine: 1- palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1′-rac-glycerol) respectively, Avanti Polar Lipids). Binding reactions contained 50 fmol functional receptor, 0.6 nM \[^3^H\] N-methyl scopolamine (NMS), 100 mM NaCl, 20 mM HEPES pH 7.5, 0.1% BSA, and ligands and nanobodies as indicated. Concentration-dependent effects of nanobodies were measured in the presence of 10 nM iperoxo. All reactions were carried out in a 500 μL volume. For samples containing G protein, purified G~i~ heterotrimer from insect cells was added to the reactions at a 1000-fold dilution from a 200 μM stock, resulting in a large stoichiometric excess over receptor and diluting G protein below the detergent CMC to allow incorporation into HDL particles, essentially as described previously^[@R39]^. Reactions were mixed and then incubated for 2 hr. Samples were then filtered on a 48-well harvester (Brandel) onto a filter which had been pre-treated with 0.1% polyethylenimine. All measurements were taken by liquid scintillation counting, and experiments were performed at least in triplicate.

Site-directed mutagenesis {#S21}
-------------------------

A mammalian expression plasmid coding for the human M~2~ muscarinic receptor (M~2~R-pcDNA3.1+) was obtained from the Missouri S&T cDNA Resource Center. Mutant M~2~ receptors were generated by using the QuikChange site-directed mutagenesis kit (Stratagene, Foster City, CA, USA) according to the manufacturer\'s instructions. The identity of all mutant M~2~ receptor constructs was confirmed by DNA sequencing.

Transient expression of receptor constructs in COS-7 cells {#S22}
----------------------------------------------------------

WT and mutant M~2~ receptors were transiently expressed in COS-7 cells grown in 100 mm dishes, as described previously^[@R40]^. For functional studies, the various receptor constructs (3 μg each) were co-expressed with a chimeric G protein α subunit (G~qi5~; 3 μg plasmid DNA) in which the last five amino acids of Gα~q~ were replaced with the corresponding Gα~i~ sequence^[@R41]^.

Radioligand binding studies of mutant and WT M~2~ receptors {#S23}
-----------------------------------------------------------

Acetylcholine (ACh) bromide was purchased from Sigma (St. Louis, MO, USA). Iperoxo was a generous gift of Bristol Myers Squibb (New York, NY). \[^3^H\]-NMS (85.5 Ci/mmol) and 3-quinuclidinyl benzilate (\[^3^H\]-QNB; 47.4 Ci/mmol) were from PerkinElmer Life Sciences (Downers Grove, IL, USA). Radioligand binding studies were carried out with membranes prepared from transfected COS-7 cells as described^[@R41]^. Forty-eight hours after transfection, cells were harvested and resuspended in 25 mM sodium phosphate buffer (pH 7.4) containing 5 mM MgCl~2~. Membrane homogenates were prepared and resuspended in the same buffer. \[^3^H\]-NMS or \[^3^H\]-QNB binding reactions were carried out in the presence of 9 μg of membrane protein for 3 hr at room temperature (total volume of the incubation mixture: 0.5 ml). In saturation binding studies, six different concentrations of the radioligand were used (\[^3^H\]-NMS, 0.3 nM to 10 nM; \[^3^H\]-QNB, 0.05 nM to 20 nM). In competition binding assays, membrane homogenates were incubated with ten different concentrations of ACh (13 nM to 1 mM) or iperoxo (0.13 nM to 10 μM) in the presence of a fixed concentration of radioligand (2 nM \[^3^H\]-NMS for all receptors except N404Q; 15 nM \[^3^H\]-QNB for N404Q and 0.5 nM \[^3^H\]-QNB for WT M~2~ receptor). Non-specific binding was determined in the presence of 10 μM atropine. Reactions were stopped by rapid filtration through GF/C filters. Data were analyzed using Prism 4.0 software (GraphPad Software, Inc., San Diego, CA).

Calcium mobilization assay {#S24}
--------------------------

COS-7 cells co-expressing WT or mutant M~2~ receptor and the hybrid G protein, G~qi5~^41^, were incubated with increasing concentrations of agonists (ACh, 5 nM to 50 μM; iperoxo, 50 pM to 0.5 μM), and increases in intracellular calcium levels were determined in 96-well plates using FLIPR technology (Molecular Devices, Sunnyvale, CA), as described in detail previously^[@R42],[@R43]^. Agonist concentration-response curves were analyzed using Prism 4.0 software.

Crystallization {#S25}
---------------

Purified M~2~ receptor was reconstituted into lipidic cubic phase by mixing with a 1.5-fold excess by mass of 10:1 (w:w) monoolein cholesterol lipid mix. Protein and lipid were loaded into glass syringes (Art Robbins Instruments, Sunnyvale, CA), and then mixed 100 times by the coupled syringe method^[@R44]^. Samples of 30 -- 100 nL in volume were spotted onto 96 well glass plates and overlaid *en bloc* with 600 nL precipitant solution for each well. Precipitant solution consisted of 10 -- 20% PEG300, 100 mM HEPES pH 7.2 -- 7.9, 1.2% 1,2,3-heptanetriol, and 20 -- 80 mM EDTA pH 8.0. Identical conditions were used to crystallize LY2119620-receptor complexes, except that the overlay precipitant solution was supplemented with 500 μM LY2119620. Crystals grew in 24 hr, and reached full size within two days. Crystals were then harvested in mesh grid loops (MiTeGen, Ithaca, NY) with 10 -- 50 crystals per loop and stored in liquid nitrogen prior to use.

Data collection {#S26}
---------------

Grids of crystals were rastered at Advanced Photon Source beamlines 23ID-B and 23ID-D. Initial rastering was performed with an 80 μm by 30 μm beam with 5-fold attenuation and 1 sec exposure, and regions with strong diffraction were sub-rastered with a 10 μm collimated beam with equivalent X-ray dose. Data collection was similarly performed with a 10 μm beam, but with no attenuation and exposures of typically 1 -- 5 s. An oscillation width of 1 -- 2 degrees was used in each case, and wedges of 5 -- 10 degrees were compiled to create the final data sets.

Data reduction and refinement {#S27}
-----------------------------

Diffraction data were processed in *HKL2000*^[@R45]^, and statistics are summarized in [Extended Data Table 1](#T1){ref-type="table"}. The structure was solved using molecular replacement with the structure of the inactive M~2~ receptor (PDB ID: 3UON) and Nb80 (PDB ID: 3P0G) as search models in *Phaser*^[@R46]^. The resulting structure was iteratively refined in *Phenix*^[@R47]^ and manually rebuilt in *Coot*^[@R48]^. Final refinement statistics are summarized in [Extended Data Table 1](#T1){ref-type="table"}. Figures were prepared in *PyMol* (Schrödinger).
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![Isolation of Nb9-8\
**a**, Nanobodies from a llama immunized with M~2~ receptor were displayed on yeast as an amino terminal fusion to Aga2p, and subjected to magnetic selection to enrich clones that bind preferentially to agonist-occupied receptor. **b**, For selections, an aziridinium ion derivative of iperoxo called FAUC123 was synthesized, allowing covalent modification of the receptor. **c**, Yeast were stained simultaneously with agonist-occupied M~2~ receptor and antagonist-occupied receptor labeled with distinct fluorophores. **d**, Yeast from each selection round (Rd. 1 -- 9) were stained in this manner to assess selection progress, showing a clear enrichment first for non-selective binders (upper right quadrants) followed by specific enrichment for agonist-preferring clones (lower right quadrants). \*Indicates a selection round employing conformational selection. \*\*Indicates a selection round using FACS.](nihms529325f1){#F1}

![M~2~ active-state specific nanobodies\
**a**, Three nanobodies were selected for detailed characterization, each with entirely unique complementarity determining region (CDR) sequences. These three nanobodies were expressed on the surface of yeast, and characterized by flow cytometry staining with FAUC123-bound (*i.e.*, agonist-bound) M~2~ receptor and tiotropium-bound (*i.e.*, antagonist-occupied) receptor. **b**, Each of the three clones displayed a preference for agonist-occupied receptor to varying degrees. **c**, Purified nanobodies were tested in a dose-response assay for their ability to suppress \[^3^H\]-NMS binding to the M~2~ receptor in the presence of 10 nM (IC~20~) iperoxo, with Nb9-8 being the most potent clone. **d**, Like the G protein G~i~, Nb9-8 caused a substantial enhancement of iperoxo affinity in a competition binding assay.](nihms529325f2){#F2}

![Intracellular changes on activation of the M~2~ receptor\
**a**, The overall structure of the active-state M~2~ receptor (orange) in complex with the orthosteric agonist iperoxo and the active-state stabilizing nanobody Nb9-8 is shown. **b**, Compared to the inactive structure of the M~2~ receptor (blue), transmembrane helix 6 (TM6) is substantially displaced outward, and TM7 has moved inward. Together, these motions lead to the formation of the G protein-binding site. **c-d**, Conserved motifs likewise show substantial changes on activation, and adopt conformations similar to those seen in the two other active GPCR structures (**e-f**). In particular, an interaction between two conserved tyrosines (Tyr^5.58^ and Tyr^7.53^) is likely mediated by a water molecule (blue circle), as seen in the high-resolution structure of the active β~2~AR \[[@R18]\].](nihms529325f3){#F3}

![Orthosteric ligand binding site\
**a**, Orthosteric ligands used for crystallization of inactive and active M~2~ receptor are shown in. **b**, Cross-sections through the receptor are shown, with the interior in black. In the inactive conformation, the receptor (blue, at left) partially encloses the antagonist QNB, while the active conformation receptor encloses the agonist entirely, such that it is completely buried within the receptor (orange, at right). **c**, Conformational changes within the ligand binding pocket are shown from the extracellular side in, with changes highlighted as red arrows. **d**, A side view shows the inward motion of TM6, which is required for the formation of a hydrogen bond between Asn404^6.52^ and the agonist iperoxo. **e**, Activation thus involves a pivot of TM6, which moves inward in the orthosteric site and outward at the intracellular side. **f**, The closure of the binding pocket allows the formation of a hydrogen bonded tyrosine lid, located superficial to the agonist.](nihms529325f4){#F4}

![Structure of a GPCR allosteric modulator complex\
**a**, The M~2~ receptor occupied by the orthosteric agonist iperoxo was crystallized in complex with the positive allosteric modulator LY2119620. **b**, The allosteric ligand binds to the extracellular vestibule just above the orthosteric agonist. A cross-section through the membrane plane shows the relative positions of the two ligands. **c**, Several polar contacts are involved in LY2119620 binding, in addition to extensive aromatic stacking interactions with Trp422^7.35^ and Tyr177^ECL2^. **d**, Upon activation, the M~2~ receptor undergoes substantial conformational changes in the extracellular surface, leading to a contraction of the extracellular vestibule. **e**, This creates a binding site that fits tightly around the allosteric modulator, which would otherwise be unable to interact extensively with the extracellular vestibule in the inactive receptor conformation.](nihms529325f5){#F5}

![Characterization of FAUC123\
**a**, Activation of M~2~ receptor by the prototypical muscarinic agonist carbachol, the high affinity agonist iperoxo, and an irreversible iperoxo analog (FAUC 123) shows that iperoxo and FAUC 123 are exceptionally potent full agonists at the M~2~ muscarinic receptor. Points indicate mean ± SEM of three independent measurements, each performed in triplicate. **b**, *Sf9* membranes expressing the human M~2~ receptor were incubated overnight at 4 °C with either no ligand, 100 μM iperoxo, or 100 μM FAUC 123. Membranes were then washed three times in buffer without ligand, and incubated with a saturating concentration (20 nM) of \[^3^H\]-NMS. Incubation with iperoxo had no effect on radioligand binding, while FAUC 123 blocked almost all \[^3^H\]-NMS binding sites. Bars indicate mean ± SEM of three independent measurements. **c**, FAUC 123 was tested for its ability to induce M~2~ receptor activation following covalent modification. While iperoxo-induced inositol phosphate production was blocked by 1 μM atropine, FAUC 123-induced activation was not susceptible to atropine blockade. Bars indicate mean ± SEM of three independent measurements.](nihms529325f6){#F6}

![Comparison to other active GPCR structures\
Structures of all activated GPCRs show similarities in conformational changes at the intracellular surface. In each case, the intracellular tip of transmembrane helix 6 (TM6) moves outward on activation, as seen in the view from the intracellular side (right panels). This creates a cavity to which a G protein can bind the receptor.](nihms529325f7){#F7}

![Pharmacology\
**a**, Functional properties are shown for M~2~ receptors in which key residues were mutated. Agonist-induced increases in intracellular calcium levels were monitored via FLIPR using transfected COS-7 cells. Since some mutant receptors (N58A, D103E) were expressed at lower levels than the WT receptor, reference curves were obtained using cells transfected with either 3 μg DNA or 1 μg WT receptor DNA. The latter cells showed receptor expression levels comparable to those found with the N58A and D103E mutants (see [Extended Data Table 2](#T2){ref-type="table"} for details). Data are given as means ± SEM of three independent experiments, each carried out in triplicate. AU, arbitrary units. **b**, The interaction between LY2119620 and iperoxo was measured by radioligand binding and functional assays. LY2119620 enhances the affinity of iperoxo (top graph) and its signaling potency (bottom graphs), and is also able to directly activate M~2~ receptor signaling as measured by \[^35^S\]GTPγS and ERK1/2 phosphorylation. Experiments were carried out with CHO cells stably expressing the human M~2~ receptor, and points are shown as mean ± SEM of three independent experiments, each carried out in duplicate.](nihms529325f8){#F8}

![Binding site diagram\
M~2~ receptor residues interacting with the orthosteric agonist iperoxo and the positive allosteric modulator LY2119620 are shown. Polar contacts are highlighted as red dotted lines, and hydrophobic contacts are in green solid lines.](nihms529325f9){#F9}

![Electron density\
**a-b**, *F~o~-F~c~* omit maps are shown in gray, contoured at 2.5 σ within a 2.5 Å radius of the indicated ligand. **c-f**, 2F~o~-F~c~ maps are shown in blue, contoured at 1.5 σ within a 2.0 Å radius of the indicated region.](nihms529325f10){#F10}

![Comparison of M~2~ receptor structures with and without LY2119620 bound\
Comparison of the structure of active M~2~ receptor with and without the allosteric modulator LY2119620 reveals that there are few differences outside the extracellular vestibule. Within the extracellular vestibule, there is a slight contraction in the presence of the modulator, and Trp422^7.35^ undergoes a change of rotamer (panel b, red arrow).](nihms529325f11){#F11}

###### Data collection and refinement statistics

                                                           M~2~ receptor:Nb9-8 complex   M~2~ receptor:Nb9-8 complex bound to LY2119620
  -------------------------------------------------------- ----------------------------- ------------------------------------------------
  **Data collection**[\*](#TFN1){ref-type="table-fn"}                                    
  Number of crystals                                       17                            18
  Space group                                              P2~1~2~1~2~1~                 P2~1~2~1~2~1~
  Unit cell dimensions                                                                   
   *a, b, c* (Å)                                           62.9,78.1,163.5               59.0,77.4,163.8
   *α,β,γ*(°)                                              90, 90, 90                    90, 90, 90
  Resolution (Å)                                           33 -- 3.5(3.6 -- 3.5)         36 -- 3.7(3.8 -- 3.7)
  R~merge~ (%)                                             18.8(74.4)                    19.5(60.5)
  \<l/σl\>                                                 5.8(1.4)                      5.6(2.1)
  CC~1/2~ (%)                                              99.1 (35.0)                   99.0(54.1)
  Completeness (%)                                         95.9(83.1)                    93.0(80.1)
  Redundancy                                               4.8                           4.8
  **Refinement**                                                                         
  Number of reflections                                    10237                         7867
  R~work~/R~free~ (%)                                      24.9 / 29.8                   25.0 / 30.1
  No. atoms                                                                              
   Protein                                                 3020                          3013
   Ligand(s)                                               14                            57
  Average B factors (Å^2^)                                                               
   Receptor                                                109.7                         102.3
   Nb6B9                                                   137.4                         129.3
   Iperoxo                                                 105.5                         107.6
   LY2119620                                               \-                            119.0
  RMS deviation from ideality                                                            
   Bond length (Å)                                         0.004                         0.004
   Bond angles (°)                                         0.86                          0.81
  Ramachandran statistics[†](#TFN2){ref-type="table-fn"}                                 
   Favored (%)                                             97.0                          95.9
   Allowed (%)                                             3.0                           4.1
   Outliers (%)                                            0                             0

Highest shell statistics in parentheses.

As calculated by Molprobity.

###### Ligand binding properties of mutant M~2~ receptors

Radioligand binding studies were carried out with membranes prepared from COS-7 cells transiently expressing the indicated mutant M~2~ receptor constructs. The WT M~2~ receptor was expressed at two different densities to allow for a more straightforward interpretation of the functional data shown in [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"} (see Online Methods for details). ACh and iperoxo binding affinities (K~i~) were determined in radioligand competition binding assays as indicated. ACh and iperoxo binding affinities (K~i~) were determined in \[^3^H\]-QNB competition binding assays for the N404Q^6.52^ mutant, which did not bind \[^3^H\]-NMS with sufficient affinity. Data are given as means ± SEM from two or three independent experiments, each performed in duplicate.

  Receptor            \[^3^H\]-NMS binding                   ACh binding   Iperoxo binding   
  ------------------- -------------------------------------- ------------- ----------------- -----------------
  WT M2               1.48 ± 0.31                            1.79 ± 0.17   2.74 ± 0.13       0.0073 ± 0.0006
  WT M~2~(1 μg DNA)   1.40 ± 0.02                            0.60 ±0.14                      
  N58A^2.39^          1.15 ± 0.05                            0.62 ± 0.14   0.84 ± 0.21       0.0053 ± 0.0012
  D103E^3.32^         2.57 ± 0.58                            0.51 ± 0.10   327 ± 91          2.76 ± 0.82
  Y206F^5.58^         1.67 ± 0.26                            1.87 ± 0.26   31.8 ±0.71        0.52 ± 0.20
  N404Q^6\ 52^        N.D.[\*](#TFN3){ref-type="table-fn"}                                   

  Receptor      \[^3^H\]-QNB binding   ACh binding   Iperoxo binding   
  ------------- ---------------------- ------------- ----------------- -----------------
  WT M~2~       0.058 ± 0.015          1.63 ± 0.19   1.25 ± 0.07       0.0130 ± 0.0070
  N404Q^6.52^   9.47 ± 2.22            1.24 ± 0.12   34.3 ± 10.3       1.70 ± 0.29

no detectable \[^3^H\]-NMS binding activity

###### Pharmacological characterization of LY2119620

**a**, Allosteric ternary complex model binding parameters for the interaction between LY2119620, iperoxo, and \[^3^H\]-NMS at the human M~2~ receptor. **b**, Operational model parameters for the functional allosteric interaction between iperoxo and LY2119620 at the human M~2~ receptor. Estimated parameter values represent the mean ± SEM of three experiments performed in duplicate.

  a                                                                  
  --------------------------------------- -------------------------- --
  pK~B~[\*](#TFN4){ref-type="table-fn"}   5.77 ± 0.10                
  pK~\|~[†](#TFN5){ref-type="table-fn"}   8.51 ± 0.04                
  Logα[‡](#TFN6){ref-type="table-fn"}     1.40 ± 0.09 (α = 25)       
  Logα\'[§](#TFN7){ref-type="table-fn"}   -0.26 ± 0.03 (α\' = 0.6)   

  b                                                       
  ---------------------------------------- -------------- -------------
  pK~B~[\*](#TFN4){ref-type="table-fn"}    5.73 ± 0.11    5.84 ± 0.18
  logαβ [‖](#TFN8){ref-type="table-fn"}    1.42 ± 0.09    1.30 ± 0.20
                                           (αβ = 26)      (αβ = 20)
  logτ~B~[¶](#TFN9){ref-type="table-fn"}   -0.28 ± 0.05   0.33 ± 0.09

Negative logarithm of the equilibrium dissociation constant of LY2119620

Negative logarithm of the equilibrium dissociation constant of iperoxo

Logarithm of the binding cooperativity factor between LY2119620 and iperoxo (antilogarithm shown in parentheses)

Logarithm of the binding cooperativity factor between LY2119620 and \[^3^H\]-NMS (antilogarithm shown in parentheses)

Logarithm of the product of the binding cooperativity (α) and activation modulation (β) factors between iperoxo and LY2119620. Antilogarithm shown in parentheses.

Logarithm of the operational efficacy parameter of LY2119620 as an allosteric agonist.

[^1]: These authors contributed equally to this work.
